Nebulized dexmedetomidine for chronic migraine and heightened pain sensitivity
Tests nebulized dexmedetomidine in adults with chronic migraine.
Plain-language title generated from the registry record
Registry title: Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
Key facts
- Where
- Banī Suwayf, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07769255, who can take part
Where in Egypt
- Beni-Suef University HospitalBanī Suwayf, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beni-Suef University
- Trial code
- NCT07769255
- Record updated
- 17 August 2026
- Original description
Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems.Read full original descriptionShow less
Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine: A Randomized Controlled Trial Using Calcitonin Gene Related Peptide and Trigeminal Neurophysiological Biomarkers
Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems.
Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .
Inclusion: Diagnosis of Early chronic migraine (<6 months of ≥15 headache days/month), per ICHD-3 criteria; No preventive migraine therapy in the prior 8 weeks.
Exclusion: Current use of sedatives, opioids, or CGRP-targeting therapies; Presence of cardiopulmonary, psychiatric, or neurological comorbidities; Pregnancy or breastfeeding.